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Fragile X-associated tremor/ataxia syndrome (FXTAS) is a severe neurodegenerative
movement disorder affecting over 40% of male and 16% of female FMR1 premutation
carriers over the age of 50. However, there is a lack of prognostic biomarkers to
aid early diagnosis and treatment planning. Therefore, this study aimed to assess the
utility of the Magnetic Resonance Parkinson Index (MRPI) as a potential MRI biomarker
for FXTAS. The four measurements required for the MRPI were assessed in 45 male
premutation carriers at risk of developing FXTAS (Mean age = 59.54 years), 53 male
patients with FXTAS (Mean age = 66.16 years) and 61 male controls (Mean age = 60.75
years), of which 73 participants had follow-up visits on average 1.96 years later. Middle
cerebellar peduncle (MCP) width as well as midbrain and pons cross-sectional area were
reduced in patients with FXTAS compared to both premutation carriers without FXTAS
and controls. While these measurements were not found to change over time in the
three-group analysis, age was an important predictor of midbrain cross-sectional area
and pons/midbrain ratio. MCP width was initially reduced in a subset of premutation
carriers who developed FXTAS symptoms between their initial and follow-up visits, which
also decreased between visits, compared to age-matched premutation carriers who did
not show any FXTAS symptom development over time. Therefore, while the MPRI may
not be a useful biomarker for FXTAS, decreased MCP width may be one of the first
notable signs of FXTAS, and therefore the first biomarker with the potential to identify
those most at risk for the disorder.
Keywords: fragile X, FXTAS, biomarkers, MRI, middle cerebellar peduncle
INTRODUCTION
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a severe neurodegenerative movement
disorder caused by premutation expansions (55–200 CGG repeats) in the 5′ untranslated region
of the fragile X mental retardation 1 (FMR1) gene, located on the X-chromosome. An estimated 1
in 209 females and 1 in 430 males carry a premutation allele (Tassone et al., 2012). Studies suggest
that∼40% of male and 8–16% of female premutation carriers over the age of 50 years (Rodriguez-
Revenga et al., 2009) have FXTAS, but these figures rise to 75% of male premutation carriers over
the age of 70 years (Jacquemont et al., 2004). Despite the relatively high incidence, there is currently
a lack of prognostic markers to detect the earliest neurodegenerative signs of FXTAS.
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The diagnostic criteria of FXTAS comprise three domains:
clinical, radiological, and pathological (Jacquemont et al., 2003;
Hall et al., 2014). Whether definite, probable or possible, FXTAS
diagnosis requires a degree of functional/clinical impairment.
While the clinical presentation is variable, the initial presenting
motor symptom is often an intention or kinetic tremor, followed
by cerebellar ataxia, both of which typically progress over
time (Apartis et al., 2012). Other clinical features may include
executive dysfunction, ranging from mild to dementia-like in
severity, which often presents later in the disease course (Seritan
et al., 2008).
The neuropathology of FXTAS is characterized by the
presence of ubiquitin-positive intracellular inclusions in neural
and astrocyte cells within the cortex and cerebellum in
post-mortem analysis (Greco et al., 2002). Currently, FXTAS
neuropathology can only be confirmed after death and hence
cannot be used as a prognostic tool.
The radiological phenotype emphasizes FXTAS as a white
matter neurodegenerative disease, as prior studies have
highlighted the presence of white matter lesions in the middle
cerebellar peduncles (MCP), known as the MCP sign, and
brainstem, as well as generalized cerebral lesions and atrophy
throughout the neocortex (Cohen et al., 2006; Rivera et al.,
2010; Hashimoto et al., 2011). Indeed, it has been suggested that
hyperintensities of the splenium of the corpus callosum should
be added as a minor criterion for FXTAS, given that these lesions
were found to be more common than MCP lesions in female
premutation carriers with FXTAS (Apartis et al., 2012). TheMCP
sign is not specific to FXTAS (Storey and Billimoria, 2005) and is
occasionally seen in other rare neurodegenerative diseases such
as sporadic olivopontocerebellar atrophy and spinocerebellar
ataxia (Brunberg et al., 2002; Quattrone et al., 2016).
Hence, the radiological criteria for FXTAS are continually
evolving, and we are still lacking a single marker that can
sensitively and specifically predict FXTAS onset or severity. The
Magnetic Resonance Parkinson Index (MRPI) has been shown
to successfully distinguish subcortical movement disorders, such
as Parkinson’s disease and progressive supranuclear palsy, both
of which present with a tremor similar to that seen in FXTAS
(Quattrone et al., 2008). Not only has the MRPI been shown
to differentiate these disorders, but it has been found to be
predictive of vertical supranuclear gaze palsy in patients affected
by progressive supranuclear palsy over time (Okamoto et al.,
2003). The MRPI is a ratio that encompasses measurements
of the MCP and superior cerebellar peduncle (SCP) widths,
as well as the cross-sectional area of the midbrain and pons;
MRPI = [(Pons area/Midbrain area) x (MCP width/SCP
width)]. These regions play an integral role within the cortico-
cerebellar pathway, which is necessary for the learning and
coordination of various movements (Ramnani, 2006). Therefore,
these measurements and their ratios may prove to be useful
biomarkers for FXTAS, a neurodegenerative movement disorder,
given thatMCP hyperintensities are a radiological sign of FXTAS,
and there are anecdotal reports of the hummingbird sign (the
Abbreviations: FXTAS, Fragile X-associated tremor/ataxia syndrome; MCP,
Middle Cerebellar Peduncle; MRPI, Magnetic Resonance Parkinsons Index.
ratio of the cross-sectional area of the midbrain and pons) being
present in some patients with FXTAS. Therefore, the aim of this
study was to assess the utility of these MRPI measurements and
ratios as radiological biomarkers for FXTAS, both in early and
later stages of the disorder.
MATERIALS AND METHODS
Participants
A total of 159 male participants over the age of 40 years
were recruited from the Sacramento, CA area and throughout
the United States and Canada as part of two continuing
and concurrent longitudinal studies (PIs: Hessl and Rivera;
Hagerman). The Institutional Review Board of UC Davis
approved this protocol and all participants gave written informed
consent before participating in the study in line with the
Declaration of Helsinki. CGG repeat length and neurological
assessment resulted in three experimental groups of participants
at visit 1: healthy controls (n= 61), premutation carriers without
FXTAS (n = 45; FXTAS stage score of 0 to 1—no or equivocal
tremor/ataxia), and premutation carriers with FXTAS (n = 53;
FXTAS stage scale score ≥2—clear tremor/ataxia with some
interference in functioning). FXTAS stage scores were based
on the clinical descriptions previously defined (Bacalman et al.,
2006). All participants were scanned at visit 1 and 73 had a follow-
up scan on average 1.96 years later (standard deviation =0.88,
range 0.75–4.79 years) (Table 1 for demographics). Twenty-five
were premutation carriers without FXTAS at visit 1, of which
10 were classified as “Converters” because they developed clear
FXTAS symptomology at visit 2 (FXTAS stage score was 0–1 at
visit 1 and ≥2 at visit 2; mean age at visit 1 = 58.81, SD = 6.17
years). We then selected 10 “Non-converters” (FXTAS stage score
was 0–1 at both visit 1 and visit 2; mean age at visit 1 = 57.95,
SD = 7.43 years), who were not showing signs of FXTAS, using
one-one age matching to use as a comparison group.
All participants were fluent English speakers, with no history
of any serious medical or neurological conditions, including
history of alcoholism or drug abuse.
CGG analysis was completed using genomic DNA isolated
from peripheral blood lymphocytes using a combination of PCR
and Southern blot analysis as previously described (Tassone
et al., 2008; Filipovic-Sadic et al., 2010). Measurements of
FMR1 mRNA expression levels were carried out by qRT-PCR as
previously detailed (Tassone et al., 2000).
MRI Acquisition
High resolution structural MRIs were acquired on a 3T Siemens
Trio Scanner using a 32-channel head coil and a T1-weighted
3D MPRAGE sequence between May 2010 and June 2017 using
the following scan sequence: TR = 2,170ms, TE = 4.86ms,
flip angle = 7◦, FoV = 256 mm2, 192 slices, 1mm slice
thickness. The scans were first aligned along the anterior-
posterior commissure line using acpcdetect (http://www.nitrc.
org/projects/art) (Ardekani and Bachman, 2009). For failed
cases, manual alignment was performed using DTI Studio
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TABLE 1 | Participant demographics.
Controls Premutation Premutation ANOVA
without FXTAS with FXTAS p-value
VISIT 1
n 61 45 53
Age (years) 60.75 (9.95) 59.54 (8.17) 66.16 (6.79) 0.001a,b
CGG 29.54 (4.56) 86.11 (24.46) 90.30 (16.41) 0.001a,c
mRNA 1.25 (0.22) 2.49 (0.86) 2.63 (0.62) 0.001a,c
VISIT 2
n 21 25 27
Age (years) 58.59 (9.03) 57.83 (7.96) 68.01 (6.87) 0.001a,b
CGG 29.94 (4.27) 86.72 (23.95) 87.81 (16.56) 0.001a,c
mRNA 1.22 (0.25) 2.47 (0.74) 2.64 (0.66) 0.001a,c
Numbers in parentheses are standard deviations.
ap < 0.05 for comparison between Controls and FXTAS.
bp < 0.05 for comparison between Premutation carriers without FXTAS and FXTAS.
cp < 0.05 for comparison between Controls and Premutation carriers without FXTAS.
(http://www.mristudio.org) (Mori et al., 1999). Then MRI bias
field correction was performed using N4 (http://stnava.github.io/
ANTs/) (Tustison et al., 2010).
MRPI Analysis
A series of independent raters (two per measure) who were
blinded to the participant age and group, visit quantitatively
assessed all MR images for the four MRPI measurements (pons
and midbrain cross-sectional areas, as well as MCP and SCP
widths) based on methods previously described (Nicoletti et al.,
2006; Quattrone et al., 2008) and detailed below.
The pons andmidbrain areas were assessed on themid-sagittal
slice, where horizontal lines were drawn through the superior and
inferior pontine notches. The midbrain was measured as the area
above the superior pontine line—midbrain tegmentum, while the
pons was the area between the two horizontal lines of the superior
and inferior notches (Figure 1A).
The width of both left and right MCPs were measured
on parasagittal slices. The linear distance of the MCP was
delineated by the peripeduncular cerebrospinal fluid spaces of
pontocerebellar cisterns, where the pons was still “intact” and
the cerebellum was fully formed (white matter connecting the
cerebellar tonsil was present; Figure 1B). Finally, the widths of
both the left and right SCPs were measured on oblique coronal
slices, at the midpoint of the SCP, when it first became separated
from the inferior colliculi. The linear distance between themedial
and lateral SCP borders was measured (Figure 1C). For both
MCP and SCP widths, a mean score was calculated by averaging
the left and right measurements for each participant.
The interrater reliability coefficients were excellent for each of
the fourMRPI scores ranging between 0.986 and 0.993. Themean
score of the raters were used for further analysis.
Along with the individual MRPI measurement scores, pons-
midbrain area ratio (Pons/Midbrain) and MCP-SCP width
ratio (MCP/SCP) were calculated, along with the MRPI
[(Pons/Midbrain)∗(MCP/SCP)] (Quattrone et al., 2008).
Statistical Analysis
Each MRPI measurement and ratio score was assessed for
normality for each group (using skewness and kurtosis) and
equal variances (Levene test). Age correlated significantly with
all MRPI measurements/ratios except for SCP width (Table S1).
Therefore, comparisons of MRPI scores were conducted with
ANCOVA analysis (age as a covariate, except for SCP width
where an ANOVA was used) using Bonferroni corrections for
post-hoc analyses for group.
To examine the relationships between the MRPI
measurements/ratios and both molecular and clinical measures
in premutation carriers with and without FXTAS (combined
group), scatter plots were used to assess linearity of relationship
and were followed by hierarchical regression analysis.
To assess change in MRPI scores between visits across the
three groups, a 2 × 3 repeated measures ANCOVA (age as a
covariate, except for SCP width where an ANOVA was used) was
used. Finally, to assess whether MRPI measurements and ratios
may be a useful biomarker for FXTAS, independent t-tests and
paired samples t-tests were used to compare the sub-samples of
Converters and Non-converters at each visit, and between visits
for each group.
A significance level of p < 0.007 was set for all group and
regression analyses, considering a Bonferroni correction for the
seven MRPI measurements/ratios examined herein. Bonferroni
post-hoc analyses were set at p< 0.050.
RESULTS
Cross-Sectional Analysis of MRPI
Measurements and Ratios
MCP width, midbrain and pons cross-sectional area as well
as pons/midbrain ratio yielded significant main effects for
group (p < 0.001) (Table 2). Post-hoc pairwise comparisons
revealed that patients with FXTAS demonstrated significantly
reduced MCP width, midbrain and pons cross-sectional
areas and increased pons/midbrain ratio (all ps < 0.001)
compared to controls (Figure 2). Patients with FXTAS also
demonstrated significantly reduced MCP width, midbrain and
pons cross-sectional areas (all ps < 0.001) and increased
pons/midbrain ratio (p< 0.002) when compared to premutation
carriers without FXTAS (Figure 2). Compared to controls,
premutation carriers without FXTAS had reduced midbrain
(p < 0.001) and pons (p < 0.006) cross-section areas
(Figure 2).
Interestingly, a main effect for age was found for midbrain
cross-sectional area and pons/midbrain ratio (p < 0.007)
following correction for multiple comparisons, as well as for
pons cross-sectional area prior to correction (p = 0.043). In
these instances, when an age × group interaction was added
to the model, the main effect of group disappeared, with the
exception of pons/midbrain ratio where it remained significant
prior to correction for multiple comparisons (p = 0.008), where
the FXTAS group had a higher ratio than both the control group
(p < 0.001) and premutation carriers without FXTAS group
(p= 0.015). Premutation carriers without FXTAS showed a trend
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FIGURE 1 | Schematic diagram showing the four MRPI measurements. Panel (A) shows the horizontal lines of the superior pontine notch which divides the midbrain
(green) and pons (red) cross-sectional areas. Panel (B) shows the line drawn to define the MCP width, which is the linear distance between the peripeduncular
cerebrospinal fluid spaces of pontocerebellar cisterns. The white arrow points to the white matter connecting the cerebellar tonsil to the deep white matter of the
cerebellum. Panel (C) shows the horizontal lines which delineate the SCP width, at the coronal slice where the SCP first separates from the inferior colliculi.
TABLE 2 | Summarized statistics (mean and standard deviations) and ANCOVA/ANOVA statistics for the main effect of group when comparing controls and premutation
carriers with and without FXTAS.
Controls Premutation Carriers
without FXTAS
Premutation Carriers
with FXTAS
F-statistic for group p-value for group η2 for group
MCP width 9.61 (1.12) 9.42 (1.06) 8.38 (1.41) 16.2 <0.001 0.172∧#
SCP width 5.09 (0.82) 5.02 (0.94) 4.97 (0.99) 0.25 0.782 0.003
Midbrain 177.4 (29.4) 159.7 (28.6) 122.8 (31.5) 48.3 <0.001 0.382*∧#
Pons 608.5 (56.9) 577.7 (62.4) 519.9 (60.1) 31.9 <0.001 0.290*∧#
SCP/MCP 1.94 (0.40) 1.93 (0.39) 1.72 (0.35) 5.44 0.005 0.065∧#
Pons/Midbrain 3.51 (0.61) 3.69 (0.55) 4.43 (0.92) 25.6 <0.001 0.248∧#
MRPI 6.84 (2.01) 7.12 (1.67) 7.60 (1.99) 2.24 0.110 0.028∧
Values in parentheses represent standard deviations. η2 represents partial eta squared; *a significant group difference between controls and premutation carriers without FXTAS (p≤ 0.05
post-hoc); ∧a significant group difference between controls and premutation carriers with FXTAS (p ≤ 0.05 post-hoc); #a significant group difference between premutation carriers with
and without FXTAS (p ≤ 0.05 post-hoc).
toward increased pons/midbrain ratio compared to controls
(p = 0.069). However, a significant age × group interaction
was found for the pons/midbrain ratio (p = 0.001), whereby
the steepest rate of incline was for the FXTAS, followed by the
premutation without FXTAS group. Age remained a significant
predictor of midbrain cross-sectional area (p < 0.001) and
pons/midbrain ratio (p < 0.001) following correction, as well
as pons cross-sectional areas (p = 0.012) prior to correction for
multiple comparisons.
Relationships Between MRPI Measurements/Ratios,
FXTAS Stage, and Molecular Markers for Premutation
Carriers
The MRPI measurements and ratios for all premutation carriers
combined revealed significant relationships with the FXTAS stage
scores (Table 3), but not for CGG or FMR1mRNA (p> 0.007) at
visit 1. However, prior to correcting for multiple comparisons,
increased CGG repeat length was found to be associated with
reduced midbrain cross-sectional area (β = −0.192, SE = 0.075,
p = 0.012), and increased pons/midbrain ratio (β = 0.210,
SE = 0.800, p = 0.010), as well as increased FMR1 mRNA
and increased pons/midbrain ratio (β = 0.172, SE = 0.084,
p= 0.042).
Comparison of MRPI Measurements/Ratios Between
Converters and Non-converters
When comparing the Converters and Non-converters MRPI
scores, converters had significantly decreased mean MCP width
at both visits (Time 1: p = 0.002, Cohen’s d = 1.587; Time 2:
p < 0.001, Cohen’s d = 1.762), in which there was almost no
overlap in scores between groups at each visit (Figure 3). Pons
cross-sectional area was also reduced in Converters compared
to Non-converters at both visits (Time 1: p = 0.013, Cohen’s
d = 1.124; Time 2: p= 0.010, Cohen’s d = 1.279), although these
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FIGURE 2 | Cross-sectional analysis of MRPI measurements at time 1, with age as a covariate. Brackets represents group differences where p < 0.05 using post-hoc
Bonferroni correction.
TABLE 3 | Relationships between MRPI measurements/ratios and the FXTAS
stage scale for all premutation carriers with and without FXTAS.
β SE p-value
MCP width −0.513 0.098 <0.001
SCP width −0.231 0.116 0.050
Midbrain cross-sectional area −0.407 0.077 <0.001
Pons cross-sectional area −0.472 0.099 <0.001
MCP/SCP −0.185 0.108 0.091
Pons/Midbrain 0.324 0.087 <0.001
MRPI 0.089 0.115 0.441
A hierarchical regression model was used, with age included for all analyses except SCP
width. β = standardized regression coefficient.
differences did not survive Bonferroni correction for multiple
comparisons (Table 4).
Longitudinal Analysis of MRPI
Measurements and Ratios
MRPI scores were not found to change significantly between
controls, premutation carriers without FXTAS and premutation
carriers with FXTAS between visits 1 and 2 except for midbrain
cross-sectional area (Main effect for group: F = 3.45, p = 0.037).
Premutation carriers without FXTAS showed a greater change
in midbrain cross-sectional area between visit 1 and visit 2 than
premutation carriers with FXTAS (F = 6.76; p= 0.011).
Changes in MRPI Measurements in FXTAS
Converters
To examine whether MRPI scores are useful biomarkers for
newly developing FXTAS cases, a mixed-effects regression model
was used to examine change in MRPI scores between visits
for those premutation carriers who received a rating of 0 or
1 (no or equivocal tremor/ataxia) on the FXTAS stage scale
at visit 1, but received a 2 or more on the same scale (clear
FIGURE 3 | Converter and non-converter group comparison of MCP width
over time. Solid lines represent p < 0.007 and surviving Bonferroni correction
for multiple comparisons, while the dotted line represents p < 0.05 and not
surviving Bonferroni correction.
tremor/ataxia with some interference in functioning) at their
second visit (Converters, n = 10). No significant differences
in MRPI measurements/ratios between visit 1 and visit 2 were
perceptible (p> 0.05).
Following these analyses, a series of paired samples t-test were
used to assess change inMRPImeasurement/ratios between visits
for Converters and Non-converters, separately for each variable.
MCP width was the only MRPI measurement/ratio to change
significantly between visits for the Converters (p= 0.032, Cohen’s
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TABLE 4 | Demographics, summarized statistics (mean and standard deviations) and comparisons (p value) between premutation carrier converters and non-converters.
Visit 1 Visit 2
Converters Non-Converters p Converters Mean Non-Converters p
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
MCP 9.03 (0.85) 10.2 (0.67) 0.002 8.73* (0.74) 10.1 (0.80) 0.001
SCP 4.94 (0.55) 5.31 (1.30) 0.412 5.08 (0.70) 5.18 (1.06) 0.812
Midbrain 153.9 (25.9) 173.4 (30.9) 0.146 150.7 (23.0) 170.3 (32.0) 0.132
Pons 549.6 (65.4) 616.4 (39.7) 0.013 544.6 (68.8) 618.4 (43.6) 0.010
MCP/SCP 1.86 (0.32) 2.02 (0.47) 0.368 1.72 (0.36) 2.00 (0.32) 0.080
Pons/Midbrain 3.62 (0.44) 3.65 (0.59) 0.911 3.64 (0.41) 3.73 (0.61) 0.706
MRPI 6.74 (1.58) 7.33 (1.94) 0.470 6.29 (1.70) 7.52 (1.96) 0.151
Values in parentheses represent standard deviations. *Indicates that a paired samples t-test between visits is p = 0.032, and significant prior to correction for multiple comparisons.
d = 0.835), although this change did not survive Bonferroni
correction for multiple comparisons (Table 4; Figure 3). No
significant changes were found for the age-matched Non-
converters (p> 0.007).
DISCUSSION
FXTAS is a progressive and severe neurodegenerative disease,
with no established prodromal or risk biomarkers. This study
shows that specific and reliably-measured neuroanatomical
changes may precede and possibly predict clinical symptom
development. First, decreasing midbrain and pons cross-
sectional areas may be an FMR1 premutation phenotype
associated with accelerated neurodegeneration. Further, and
perhaps more interestingly, decreasing MCP width appears to
be sensitive to early structural changes associated with FXTAS
development. With larger validation and sensitivity studies, this
measure could represent a clinically useful biomarker for FXTAS
risk.
The hummingbird signal (increase in pons to midbrain
cross-sectional area ratio), suggests advanced atrophy of the
midbrain compared to the pons (Kato et al., 2003). In this
study, we found systematic atrophy of both the midbrain
and pons, and thus an increase pons/midbrain ratio in both
FMR1 premutation carriers with and without FXTAS, as well as
accelerated age-related increase in the pons/midbrain ratio in the
FXTAS group (and a trend for the FMR1 premutation carriers
without FXTAS group) compared to controls. However, the
close to significant relationships between increased CGG repeat
length, decreased midbrain cross-sectional area, and increased
pons/midbrain ratio, may suggest that the hummingbird signal
and preferential atrophy of the midbrain is more likely to occur
in FMR1 premutation carriers with high CGG repeats, who
have previously been found to have the greatest FXTAS-related
movement impairment (Leehey et al., 2008).
FMR1 premutation age-related atrophy has been previously
detected in patients with FXTAS compared to controls and
premutation carriers without FXTAS when examining brainstem
volumes (combined volume of midbrain, pons, and medulla)
(Wang et al., 2017). Thus, the findings of the current study
compliment these prior findings, and extend them to suggest
that FXTAS related neurodegeneration may accelerate otherwise
normal age-related decreases in midbrain and pons cross-
sectional areas, with the hummingbird signal (or increased
midbrain compared to pons atrophy) appearing in those with
greater CGG repeat lengths.
In addition, the pons is an important relay area for neural
pathways with cortical—cerebellar links. While changes between
visits in pons cross-sectional area were not found in this study,
the tendency for reduced volumes (even if they did not survive
multiple correction) between Converters and Non-converters is
striking. Indeed, pontine linear dimensions and white matter
density reductions have been previously documented in older
FMR1 premutation carriers with FXTAS (Brunberg et al., 2002;
Moore et al., 2004). Hence, with a larger sample of converters and
greater statistical power, measuring the cross-sectional area of the
pons may be fruitful for FXTAS diagnosis and risk assessment.
The MCP has been recognized as a critical area of pathology
and a key MRI indicator of FXTAS (Jacquemont et al., 2003;
Rivera et al., 2010; Hall et al., 2014). However, the neuropathology
that causes the increased T2 MRI signal—or hyperintensity—is
currently unknown and does not exclusively occur in FXTAS.
Indeed, theMCP pathway itself plays an important role in cortical
connections to the cerebellum, and thus it is logical that the
MCP width significantly correlated with FXTAS stage score,
which emphasizes tremor and ataxia. Although speculative,
perhaps the lack of CGG or FMR1 mRNA associations with
MCP width means that the microstructure changes that cause
the MCP signal may be in part due to decreased tract integrity
resulting from FMR1 exon 1 methylation mediated pathways
as previously hypothesized (Shelton et al., 2017), rather than
those directly related to FMR1 expression levels. We are
currently examining the relationships between white matter
hyperintensities, microstructural integrity and morphological
changes in the MCP. It is critical to better understand the
neuropathological changes that contribute to the development
and progression of FXTAS symptoms.
Out of the four measurements and three ratios, the MCP
width appears to be the best biomarker for FXTAS conversion
in those FMR1 premutation carriers most at risk, which survived
a strict Bonferroni correction. This stems from both the
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cross-sectional analysis of the three groups at visit one, and
comparison of Converters and Non-converters. Firstly, it was the
only measure in which group differences were revealed between
patients with FXTAS and both controls and premutation carriers
without FXTAS, yet no difference was found between controls
and premutation carriers without FXTAS. This is unlike the
results from the midbrain, pons areas and pons/midbrain ratio,
where differences were found between controls and premutation
carriers without FXTAS. Further, MCP width was the only
measure that reliably detected a difference between converters
and non-converters, with an indication that it even decreased as
FXTAS symptoms develop over an average period of 2.16 years.
Together, these results suggest thatMCPwidthmay be a clinically
useful biomarker for FXTAS, as it was sensitive to FXTAS onset
and progression, but not the FMR1 phenotype more generally.
Further, the findings highlight the importance of continually
tracking the MCP width of FMR1 premutation carriers to verify
its predictive value for FXTAS development.
While the results reported here are compelling, the study is
not without limitations. Given the longitudinal aspect of this
project, it is critically important that we continue to follow
and track the progression of these biomarkers in conjunction
with various neurological and neuropsychological symptoms,
in particular motor control, balance and ataxia, and executive
function (Shickman et al., 2018). Indeed, it will be critical to
confirm whether or not the current group of non-converters
remains asymptomatic, and if these findings remain in a larger
cohort of Converters andNon-converters. Thus as we continue to
collect follow-up scans, we expect to seemore FMR1 premutation
carriers convert to FXTAS, whichwill increase the power to detect
change over time, and perhaps predict how soon conversion may
occur.
Overall, these results support the hypothesis that specific
neuroanatomical changes precede and are related to FXTAS
symptom severity. Indeed, it appears that atrophy of themidbrain
and pons cross-sectional area may be a common phenotypic
characteristic for FMR1 premutation carriers, while reductions
in MCP width may be prognostic to FXTAS symptoms and
progression. While we endeavor to assess to clinical viability
of MCP width as a biomarker of FXTAS through our ongoing
research, we compel clinicians to monitor and assess changes in
the MCP, primarily for atrophy in width and hyperintensities, as
well as other FXTAS radiological signs in premutation carriers
at risk for FXTAS or with subtle non-specific clinical changes
e.g., (Shickman et al., 2018). In sum, MCP width in FMR1
premutation carriers may be a candidate biomarker to clinically
identify patients in prodromal and early stages of FXTAS to help
guide candidates for treatment and perhaps monitor response.
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